The findings above indicate that EGFR, GP73, and PD-L1 synergistically promote cancer, promising that combining EGFR inhibitors with PD-L1 antibodies can reverse GP73-mediated effects, enhancing CD8+ T cell infiltration and inhibiting tumor growth (91). Here, GOLM1 is linked to neoplasm.